Role of metallothionein 1E in the migration and invasion of human glioma cell lines

Ryu,Hyang-Hwa; Jung,Shin; Jung,Tae-Young; Moon,Kyung-Sub; Kim,In-Young; Jeong,Young-Il; Jin,Shu-Guang; Pei,Jian; Wen,Min; Jang,Woo-Yeol

doi:10.3892/ijo.2012.1570

Role of metallothionein 1E in the migration and invasion of human glioma cell lines

Authors:
- Hyang-Hwa Ryu
- Shin Jung
- Tae-Young Jung
- Kyung-Sub Moon
- In-Young Kim
- Young-Il Jeong
- Shu-Guang Jin
- Jian Pei
- Min Wen
- Woo-Yeol Jang
View Affiliations

Affiliations: Department of Brain Tumor Research Laboratory, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Gwangju, Republic of Korea, Department of Neurosurgery, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Gwangju, Republic of Korea, Department of Brain Tumor Research Laboratory, Chonnam National University Research Institute of Medical Sciences, Chonnam National University Hwasun Hospital and Medical School, Gwangju, Republic of Korea;
Published online on: July 24, 2012 https://doi.org/10.3892/ijo.2012.1570
Pages: 1305-1313

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metallothionein 1E (MT1E) has been found to be highly expressed in motile cell lines. We investigated whether MT1E actually modulates the migration and invasion of human glioma cell lines and the types of factors that have an effect on MT1E. RNA differential display was performed using Genefishing™ technology in the human glioma cell lines U343MG-A, U87MG and U87MG-10'; the results were validated by RT-PCR and northern blot analysis, in order to detect possible genetic changes as the determining factors for migration ability in malignant glioma. MT1E was identified in U87MG, a highly motile cell line. The migration and invasion abilities of human glioma cell lines, and MT1E transfectants were investigated using simple scratch testing and Matrigel invasion assays. Morphological and cytoskeletal (actin, vimentin) changes were documented by light and confocal microscopy. The expression of MT1E in four glioma cell lines was assessed by RT-PCR and western blotting. In addition, the effects of MT1E on the activity of the NF-κB p50/p65 transcription factor, MMP-2 and -9 were examined by western blotting and zymography. The endogenous MT1E expression in the human glioma cell lines was statistically correlated with their migratory abilities and invasion. The U87-MT-AS cells became more round and had decreased stress fibers, compared with the U87MG cells. Endogenous MT1E expression in the four human glioma cell lines was directly correlated with migration. Two antisense MT1E-transfected cell lines showed decreased NF-κB p50 translocation into the nucleus, which led to decreased activity of MMP-9 in conditioned media. It may be postulated that MT1E can enhance the migration and invasion of human glioma cells by inducing MMP-9 inactivation via the upregulation of NF-κB p50.

View Figures

View References

1	Kassis J, Lauffenburger DA, Turner T and Wells A: Tumor invasion as dysregulated cell motility. Semin Cancer Biol. 11:105–117. 2001. View Article : Google Scholar : PubMed/NCBI
2	Mariani L, McDonough WS, Hoelzinger DB, Beaudry C, Kaczmarek E, Coons SW, Giese A, Moghaddam M, Seiler RW and Berens ME: Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res. 61:4190–4196. 2001.PubMed/NCBI
3	Coffey DS: Prostate cancer metastasis: talking the walk. Nat Med. 2:1305–1306. 1996. View Article : Google Scholar : PubMed/NCBI
4	Levine MD, Liotta LA and Stracke ML: Stimulation and regulation of tumor cell motility in invasion and metastasis. EXS. 74:157–179. 1995.PubMed/NCBI
5	Kim YJ, Kwak CI, Gu YY, Hwang IT and Chun JY: Annealing control primer system for identification of differentially expressed genes on agarose gels. Biotechniques. 36:424–430. 2004.PubMed/NCBI
6	Ryu HH, Jung S, Sun HS, Jung TY, Jin SG, Jin YH, Kim IY, Jeong YI and Kang SS: Screening for motility-associated genes in malignant astrocytoma cell lines. J Neurooncol. 82:125–131. 2007. View Article : Google Scholar : PubMed/NCBI
7	Cai L and Cherian MG: Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium-metallothioneins. Toxicol Lett. 136:193–198. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ebadi M, Leuschen MP, el Refaey H, Hamada FM and Rojas P: The antioxidant properties of zinc and metallothionein. Neurochem Int. 29:159–166. 1996. View Article : Google Scholar : PubMed/NCBI
9	Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science. 241:1813–1815. 1988. View Article : Google Scholar : PubMed/NCBI
10	Roesijadi G: Metal transfer as a mechanism for metallothionein-mediated metal detoxification. Cell Mol Biol (Noisy-le-grand). 46:393–405. 2000.PubMed/NCBI
11	Satoh M, Cherian MG, Imura N and Shimizu H: Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res. 54:5255–5257. 1994.PubMed/NCBI
12	Maret W, Jacob C, Vallee BL and Fischer EH: Inhibitory sites in enzymes: zinc removal and reactivation by thionein. Proc Natl Acad Sci USA. 96:1936–1940. 1999. View Article : Google Scholar : PubMed/NCBI
13	Meplan C, Richard MJ and Hainaut P: Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene. 19:5227–5236. 2000. View Article : Google Scholar : PubMed/NCBI
14	Jayasurya A, Bay BH, Yap WM and Tan NG: Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br J Cancer. 82:1198–1203. 2000.PubMed/NCBI
15	Nagel WW and Vallee BL: Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci USA. 92:579–583. 1995. View Article : Google Scholar : PubMed/NCBI
16	Ghosh S, May MJ and Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 16:225–260. 1998. View Article : Google Scholar : PubMed/NCBI
17	Andela VB, Gordon AH, Zotalis G, Rosier RN, Goater JJ, Lewis GD, Schwarz EM, Puzas JE and O’Keefe RJ: NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res. S75–S85. 2003. View Article : Google Scholar : PubMed/NCBI
18	Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 107:241–246. 2001. View Article : Google Scholar : PubMed/NCBI
19	Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2:301–310. 2002. View Article : Google Scholar : PubMed/NCBI
20	Butcher HL, Kennette WA, Collins O, Zalups RK and Koropatnick J: Metallothionein mediates the level and activity of nuclear factor kappa B in murine fibroblasts. J Pharmacol Exp Ther. 310:589–598. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kim CH, Kim JH, Lee J and Ahn YS: Zinc-induced NF-kappaB inhibition can be modulated by changes in the intracellular metallothionein level. Toxicol Appl Pharmacol. 190:189–196. 2003. View Article : Google Scholar : PubMed/NCBI
22	Nakajima M and Chop AM: Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol. 2:115–127. 1991.PubMed/NCBI
23	Hiura T, Khalid H, Yamashita H, Tokunaga Y, Yasunaga A and Shibata S: Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer. 83:2361–2369. 1998. View Article : Google Scholar : PubMed/NCBI
24	Maier H, Jones C, Jasani B, Ofner D, Zelger B, Schmid KW and Budka H: Metallothionein overexpression in human brain tumours. Acta Neuropathol. 94:599–604. 1997. View Article : Google Scholar : PubMed/NCBI
25	Gallicchio LM, Flaws JA, Fowler BA and Ioffe OB: Metallothionein expression in invasive and in situ breast carcinomas. Cancer Detect Prev. 29:332–337. 2005. View Article : Google Scholar : PubMed/NCBI
26	Jin R, Bay BH, Chow VT and Tan PH: Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat. 66:265–272. 2001. View Article : Google Scholar : PubMed/NCBI
27	Winge DR: Limited proteolysis of metallothioneins. Methods Enzymol. 205:438–447. 1991. View Article : Google Scholar : PubMed/NCBI
28	Florianczyk B: Copper and metallothioneins in cancer cells. Ann Univ Mariae Curie Sklodowska Med. 58:390–393. 2003.PubMed/NCBI
29	Nartey NO, Banerjee D and Cherian MG: Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of fetal human liver and kidney and its changes during development. Pathology. 19:233–238. 1987. View Article : Google Scholar : PubMed/NCBI
30	Sato M and Bremner I: Oxygen free radicals and metallothionein. Free Radic Biol Med. 14:325–337. 1993. View Article : Google Scholar : PubMed/NCBI
31	Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 533:201–209. 2003. View Article : Google Scholar : PubMed/NCBI
32	Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M and Waalkes MP: Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci. 73:294–300. 2003. View Article : Google Scholar : PubMed/NCBI
33	Zeng J, Vallee BL and Kagi JH: Zinc transfer from transcription factor IIIA fingers to thionein clusters. Proc Natl Acad Sci USA. 88:9984–9988. 1991. View Article : Google Scholar : PubMed/NCBI
34	Yamamoto Y and Gaynor RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 107:135–142. 2001. View Article : Google Scholar : PubMed/NCBI
35	Zangger K, Oz G, Haslinger E, Kunert O and Armitage IM: Nitric oxide selectively releases metals from the amino-terminal domain of metallothioneins: potential role at inflammatory sites. FASEB J. 15:1303–1305. 2001.PubMed/NCBI
36	Coyle P, Philcox JC, Carey LC and Rofe AM: Metallothionein: the multipurpose protein. Cell Mol Life Sci. 59:627–647. 2002. View Article : Google Scholar : PubMed/NCBI
37	Kanekiyo M, Itoh N, Kawasaki A, Tanaka J, Nakanishi T and Tanaka K: Zinc-induced activation of the human cytomegalovirus major immediate-early promoter is mediated by metallothionein and nuclear factor-kappaB. Toxicol Appl Pharmacol. 173:146–153. 2001. View Article : Google Scholar : PubMed/NCBI
38	Miyamoto H, Altuwaijri S, Cai Y, Messing EM and Chang C: Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog. 44:1–10. 2005. View Article : Google Scholar
39	Abdel-Mageed AB and Agrawal KC: Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. Cancer Res. 58:2335–2338. 1998.PubMed/NCBI
40	Haga A, Nagase H, Kito H and Sato T: Enhanced invasiveness of tumour cells after host exposure to heavy metals. Eur J Cancer. 32A:2342–2347. 1996. View Article : Google Scholar : PubMed/NCBI
41	Kim HG, Kim JY, Han EH, Hwang YP, Choi JH, Park BH and Jeong HG: Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast caner cells. FEBS Lett. 585:421–428. 2011. View Article : Google Scholar : PubMed/NCBI